Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peptison is a semi-elemental, peptide-based enteral nutrition formula designed for patients with impaired gastrointestinal function or malabsorption. It provides nitrogen in the form of short-chain peptides (oligopeptides), which are more readily absorbed than whole proteins, making it particularly effective for patients with inflammatory bowel disease (IBD), Crohn's disease, or those recovering from major gastrointestinal surgeries such as esophagectomy. Clinical evidence suggests that Peptison, when used as exclusive enteral nutrition (EEN), can induce remission in Crohn's disease by reducing mucosal inflammation and downregulating pro-inflammatory cytokines, specifically interleukin-17A (IL-17A). It is typically administered via a nasogastric or jejunal tube.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peptison.